Your browser doesn't support javascript.
loading
A novel fixed-dose combination treatment for chronic hepatitis C, based on NS5A inhibitor fopitasvir and NS5B inhibitor sofosbuvir.
Zhou, Shu-Yan; Chen, Xin-Yi; Chen, Yan; Meng, Na-Na; Tao, Xin; He, Hua-Long; Liu, Zhi-Hao; Wang, Ning-Yu; Yu, Luo-Ting.
Afiliação
  • Zhou SY; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu.
  • Chen XY; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu.
  • Chen Y; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu.
  • Meng NN; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu.
  • Tao X; Changzhou Yinsheng Pharmaceutical Company, Changzhou.
  • He HL; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu.
  • Liu ZH; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu.
  • Wang NY; School of Life Science and Engineering, Southwest JiaoTong University, Chengdu, China;, Email: wangny-swjtu@swjtu.edu.cn.
  • Yu LT; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu;, Email: yuluot@scu.edu.cn.
Pharmazie ; 76(8): 372-378, 2021 08 01.
Article em En | MEDLINE | ID: mdl-34412736
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatite C Crônica / Sofosbuvir Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatite C Crônica / Sofosbuvir Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article